Surgical Thoracic Society Risk Score and EuroSCORE-2 Appropriately Assess 30-Day Postoperative Mortality in the STICH Trial and a Contemporary Cohort of Patients With Left Ventricular Dysfunction Undergoing Surgical Revascularization
Surgical Thoracic Society Risk Score and EuroSCORE-2 Appropriately Assess 30-Day Postoperative Mortality in the STICH Trial and a Contemporary Cohort of Patients With Left Ventricular Dysfunction Undergoing Surgical Revascularization
复制标题
DOI：
10.1161/circheartfailure.118.005531
复制
发表时间：
2018-11-01
影响因子：
9.7
通讯作者：
Rouleau, Jean L.
中科院分区：
文献类型：
--
作者：
Bouabdallaoui, Nadia;Stevens, Susanna R.;Rouleau, Jean L.
背景：STICH 试验（缺血性心力衰竭的手术治疗）证明，冠状动脉旁路移植术对缺血性心肌病和左心室功能障碍患者具有生存获益。胸外科协会 (STS) 风险评分和 EuroSCORE-2 (ES2) 用于心脏手术风险评估，但关于其在左心室功能障碍患者中的准确性的信息很少。我们评估了 STICH 和当代左心室射血分数患者队列 (CC) 中 STS 评分和 ES2 评估术后 30 天死亡风险的能力
BACKGROUND: The STICH trial (Surgical Treatment for Ischemic Heart Failure) demonstrated a survival benefit of coronary artery bypass grafting in patients with ischemic cardiomyopathy and left ventricular dysfunction. The Surgical Thoracic Society (STS) risk score and the EuroSCORE-2 (ES2) are used for risk assessment in cardiac surgery, with little information available about their accuracy in patients with left ventricular dysfunction. We assessed the ability of the STS score and ES2 to evaluate 30-day postoperative mortality risk in STICH and a contemporary cohort (CC) of patients with a left ventricle ejection fraction